Ranbaxy Laboratories Inc. (RLI) is committed to developing
a distinguished branded pharmaceutical business. The
foundation for establishing the branded business rests
on three strategic pillars:
|
Licensing/acquisitions |
|
In-house product development |
|
Marketing alliances. |
RLI is actively looking to acquire more products to augment
product offerings to its customers.
An important factor of the growth of Ranbaxy’s branded
business is product development expertise. In addition to research
on New Chemical Entities (NCE), Ranbaxy has highly developed
capabilities in Novel Drug Delivery Systems (NDDS) that offer
new and improved formulations to currently available chemical
entities. For example, Ranbaxy developed a once-daily formulation
of the anti-infective Cipro® (ciprofloxacin) which it has
licensed to Bayer, the original marketer of the drug.
Ranbaxy hopes to take advantage of its product development expertise
by launching its own proprietary brands, which are currently
at various stages of development.
Having a well defined branded product portfolio, the company
is actively looking for marketing partners with complimentary
skills and needs.
RLI's branded prescription division in the U.S. market will
expand and grow through Ranbaxy’s R&D efforts, continued
exploration of NDDS, licensing activities and mergers and acquisitions.
RLI's commitment to invest significantly in R&D will translate
into the development of innovative, brand name products with
a wide range of therapeutic uses.
|
